Citations

Showing 10 of 108083 citations.

Editorial Comment
Colicchia, Michele , Karnes, R. Jeffrey

Mayo Clinic

Journal of Urology | August 8, 2017 | Volume: 198 | Issue: 5 | Pages: 1084-1084

10.1016/j.juro.2017.06.101 | PMID 28801257 Get It

Comparative Cost Analysis of Endoscopic versus Microscopic Endonasal Transsphenoidal Surgery for Pituitary Adenomas
Eseonu, Chikezie I. , ReFaey, Karim , García, Óscar , Salvatori, Roberto , Quiñones‐Hinojosa, Alfredo , ReFaey, Karim

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | August 8, 2017 | Volume: 79 | Issue: 02 | Pages: 131-138

10.1055/s-0037-1604484 | PMID 29868317 Get It

Objective This study presents a comparative analysis of cost efficacy between the microscopic and endoscopic transsphenoidal approaches, evaluating neurological outcome, extent of resection (EOR), and inpatient hospital costs. Design This study was a retrospective chart review. Setting This study was conducted at a tertiary care center. Participants The study group consisted of 68 patients with transsphenoidal surgeries between January 2007 and January 2014. Main Outcome Measures Two-sample t-tests and Pearson's chi-square test evaluated inpatient costs, quality-adjusted life years (QALYs), volumetric EOR, and neurological outcomes. Results Total inpatient costs per patient was $22,853 in the microscopic group and less ($19,736) in the endoscopic group (p = 0.049). Operating room costs were $5,974 in the microscopic group and lower in the endoscopic group ($5,045; p = 0.038). Operative time was 203.6 minutes in the microscopic group and 166.3 minutes in the endoscopic group (p = 0.032). The QALY score, length of hospital stay, and postoperative outcomes were found to be similar between the two cohorts. Multivariate linear regression modeling suggested that length of stay (p < 0.001) and operative time (p = 0.008) were important factors that influenced total inpatient costs following transsphenoidal surgery. Conclusion This study shows that transsphenoidal surgery is more cost effective with the endoscopic approach than with the microscopic approach and depends on efficiency in the operating room as well as reduction in the length of hospitalization.
Retracted Article: Management of Spontaneous Labor in Primigravidae: Labor Scale versus WHO Partograph (SLiP Trial) Randomized Controlled Trial
Tolba, Sara M., Ali, Shymaa S., Mohammed, Abdelrahman, Michael, Armia , Abbas, Ahmed M. , Nassr, Ahmed A. , Shazly, Sherif A.

Mayo Clinic

American Journal of Perinatology | August 8, 2017 | Volume: 35 | Issue: 01 | Pages: 048-054

10.1055/s-0037-1605575 | PMID 28787749 Get It

The Thermodynamic Effects of Ligand Structure on the Molecular Recognition of Mono‐ and Biruthenium Polypyridyl Complexes with G‐Quadruplex DNA
Mikek, Clinton G. , Machha, Venkata R. , White, Jake C., Martin, Logan R. , West, Savannah J. , Butrin, Arseniy, Shumaker, Carmen, Gwin, J. Cole, Alatrash, Nagham , MacDonnell, Frederick M. , Lewis, Edwin A.

Mayo Clinic

European Journal of Inorganic Chemistry | August 8, 2017 | Volume: 2017 | Issue: 33 | Pages: 3953-3960

10.1002/ejic.201700789 Get It

Isothermal titration calorimetry (ITC) and circular dichroism (CD) were used to study the thermodynamics of RPC·G‐quadruplex DNA (G4) complex formation. The ruthenium polypyridyl complexes (RPCs) were [Ru(phen)3]2+ (12+), [Ru(phen)2(dppz)]2+ (22+), [Ru(phen)2(tatpp)]2+ (32+), and [Ru(phen)2(tatpp)(phen)2Ru]4+ (44+), and target DNAs were c‐MYC NHE‐III1 promoter sequence mutants forming 1‐2‐1 and 1‐6‐1 G‐quadruplexes. Formation of the 2:1 RPC·G4 complexes is characterized by entropy driven RPC binding to the top and bottom of G‐tetrad faces. 12+ appears to bind very weakly or not at all to G4 DNA. 22+ having a dipyridophenazine group to stack on the top and bottom of the G4 core, exhibits an average Ka = 6.7 × 104 m–1. 32+, with a larger G4 interactive tetraazatetrapyridopentacene group, binds with significantly higher affinity, Ka = 1.1 × 106 m–1. 22+ and 32+ appear to bind independently of G4 folding topology and RPC conformation. The thermograms for the titration of G4 DNA with rac‐44+ are characterized by two binding modes exhibiting higher and lower affinity (Ka,1 = 3.6 × 107 m–1 and Ka,2 = 3.2 × 105 m–1). The two binding modes are attributed to preferential binding of one of the 44+ enantiomers (e.g. ΛΛ) over the other isomers (e.g. ΔΔ or ΔΛ). Tighter binding of the preferred 44+ enantiomer, in comparison to 32+, is due to additional favorable entropy for locating a second [(phen)2Ru–]2+ moiety in a G4 groove. Weaker binding of the disfavored 44+ isomers must be due to a poorer fit of these isomers with the G4 faces.
Positioning Newer Agents: Riociguat, Selexipag, and Oral Treprostinil in the Current Landscape
Frantz, Robert P.

Mayo Clinic

Advances in Pulmonary Hypertension | August 8, 2017 | Volume: 15 | Issue: 4 | Pages: 193-197

10.21693/1933-088x-15.4.193 Get It

The availability of newer oral agents for therapy of pulmonary arterial hypertension entails both opportunity and uncertainty. There is the opportunity for less intrusive therapy and the potential to further lessen risk of disease progression, but there is also uncertainty regarding optimal role of these agents, concern about their expense, and risk of preventable deterioration if these agents are used in settings that clearly warrant parenteral prostanoids. Among the newer agents, the evidence is strongest for the use of the prostacyclin receptor agonist selexipag, which has been shown to reduce events in functional class II and III patients, even in the setting of background therapy with a phosphodiesterase type 5 (PDE5) inhibitor and an endothelin receptor antagonist. Riociguat is a soluble guanylate cyclase stimulator that has been shown to be beneficial, including in combination with an endothelin receptor antagonist, and may be a useful alternative to a PDE5 inhibitor in properly selected patients. It has also been shown to be beneficial in inoperable or residual thromboembolic pulmonary hypertension. Oral treprostinil has been shown to improve 6-minute walk distance as monotherapy, and has been used to transition from inhaled or parenteral treprostinil in carefully selected patients also on other agents. Herein we discuss the mechanisms of action, side effect profiles, and clinical trial data for these agents, followed by a practical approach to their use, integrating the available data with real-world experience.
Guest Editor's Memo
Schilz, Robert , Burger, Charles D.

Mayo Clinic

Advances in Pulmonary Hypertension | August 8, 2017 | Volume: 15 | Issue: 4 | Pages: 178-178

10.21693/1933-088x-15.4.178b Get It

Editor's Memo
Burger, Charles D.

Mayo Clinic

Advances in Pulmonary Hypertension | August 8, 2017 | Volume: 15 | Issue: 4 | Pages: 178-178

10.21693/1933-088x-15.4.178a Get It

Early Onset Prosthetic Joint Infection and Bacteremia due toCampylobacter fetusSubspeciesfetus
Dumic, Igor , Sengodan, Mohan, Franson, Joni J., Zea, Diego, Ramanan, Poornima , Dumic, Igor

Mayo Clinic

Case Reports in Infectious Diseases | August 8, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-6

10.1155/2017/5892846 | PMID 28928998 Get It

Campylobacter fetusis a zoonotic pathogen that occasionally causes serious, relapsing, invasive disease, especially in immunocompromised hosts. We report a case of relapsingC. fetusdiarrheal illness in a 75-year-old woman which resulted in secondary bacteremia and seeding of the left knee prosthetic joint. Patient responded favorably to debridement and retention of prosthesis in addition to six weeks of meropenem followed by chronic oral doxycycline suppressive therapy.
Disease understanding in patients newly diagnosed with atrial fibrillation
Kaufman, Brystana G. , Kim, Sunghee , Pieper, Karen S. , Ezekowitz, Michael D. , Mahaffey, Kenneth W. , Singer, Daniel E. , Ansell, Jack , Kowey, Peter R. , Rieffel, James A, Piccini, Jonathan P. , O’Brien, Emily C. , Allen, Larry A. , Gersh, Bernard J. , Naccarelli, Gerald V. , Fonarow, Gregg C. , Chan, Paul S. , Freeman, James V. , Peterson, Eric D.

Mayo Clinic

Heart | August 8, 2017 | Volume: 104 | Issue: 6 | Pages: 494-501

10.1136/heartjnl-2017-311800 | PMID 28790169 Get It

Objective To describe self-reported disease understanding for newly diagnosed patients with atrial fibrillation (AF) and assess (1) how disease understanding changes over the first 6 months after diagnosis and (2) the relationship between patient understanding of therapies at baseline and treatment receipt at 6 months among treatment-naïve patients. Methods We analysed survey data from SATELLITE (Survey of Patient Knowledge and Personal Priorities for Treatment), a substudy of patients with new-onset AF enrolled in the national Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) II registry across 56 US sites. Patients were surveyed at the baseline and 6-month follow-up clinic visits using Likert scales. Results Among 1004 baseline survey responses, patients’ confidence in their understanding of rhythm control, ablation, anticoagulation and cardioversion was suboptimal, with ‘high’ understanding ranging from 8.5% for left atrial appendage closure to 71.3% for rhythm therapy. Of medical history and demographic factors, education level was the strongest predictor of reporting ‘high’ disease understanding. Among the 786 patients with 6-month survey data, significant increases in the proportion reporting high understanding were observed (p<0.05) only for warfarin and direct oral anticoagulants (DOACs). With the exception of ablation, high understanding for a given therapeutic option was not associated with increased use of that therapy at 6 months. Conclusions About half of patients with new-onset AF understood the benefits of oral anticoagulant at the time of diagnosis and understanding improved over the first 6 months. However, understanding of AF treatment remains suboptimal at 6 months. Our results suggest a need for ongoing patient education. Clinical trial registration Clinicaltrials.gov. Identifier: NCT01701817.
Structural and Functional Changes in Human Kidneys with Healthy Aging
Hommos, Musab S. , Glassock, Richard J. , Hommos, Musab S , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | August 8, 2017 | Volume: 28 | Issue: 10 | Pages: 2838-2844

10.1681/asn.2017040421 | PMID 28790143 Get It

Aging is associated with significant changes in structure and function of the kidney, even in the absence of age-related comorbidities. On the macrostructural level, kidney cortical volume decreases, surface roughness increases, and the number and size of simple renal cysts increase with age. On the microstructural level, the histologic signs of nephrosclerosis (arteriosclerosis/arteriolosclerosis, global glomerulosclerosis, interstitial fibrosis, and tubular atrophy) all increase with age. The decline of nephron number is accompanied by a comparable reduction in measured whole-kidney GFR. However, single-nephron GFR remains relatively constant with healthy aging as does glomerular volume. Only when glomerulosclerosis and arteriosclerosis exceed that expected for age is there an increase in single-nephron GFR. In the absence of albuminuria, age-related reduction in GFR with the corresponding increase in CKD (defined by an eGFR<60 ml/min per 1.73 m 2 ) has been shown to associate with a very modest to no increase in age-standardized mortality risk or ESRD. These findings raise the question of whether disease labeling of an age-related decline in GFR is appropriate. These findings also emphasize the need for a different management approach for many elderly individuals considered to have CKD by current criteria.